Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P210027/S016

QDOT MICRO System

Biosense Webster, Inc. · Decision date Apr 17, 2026

FDA DECISIONP210027/S016

What did the FDA approve?

FDA records P210027/S016 as a supplement to PMA P210027, with the supplement type “Special (Immediate Track)”. The recorded decision is approval, dated Apr 17, 2026.

FDA approval order statement

approval for modifications to the device labeling, including addition of information related to potential adverse reactions
Regulatory pathway
PMA supplement
Supplement type
Special (Immediate Track)
Clinical specialty
Cardiovascular
Decision date
Apr 17, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P210027/S016
Regulatory pathway
PMA supplement
Product code
OAE
Decision code
APPR
Decision date
Apr 17, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Catheter, percutaneous, cardiac ablation, for treatment of atrial fibrillation.

Product code
OAE
FDA device class
3

For the original device and its historical approval scope, see PMA P210027. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P210027 · Original PMA

    QDOT MICRO System

  2. P210027/S016 received

    Application receipt date recorded by FDA.

  3. P210027/S016 · FDA decision

    Special (Immediate Track)

  4. P210027/S019 · Related supplement

    QDOT MICRO BI-DIRECTIONAL NAVIGATION CATHETER; QDOT MICRO UNI-DIRECTIONAL NAVIGATION CATHETER

Timeline entries are records held by MedtechLedger for P210027. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P210027

Product / regulatory recordCompanyPathwayDecision dateSource
Biosense Webster, Inc.PMA approvalNov 23, 2022FDA
TX eco CableP210027/S017
Biosense Webster, Inc.PMA supplementAug 17, 2026FDA
QDOT MICRO SystemP210027/S018
Biosense Webster, Inc.PMA supplementSep 10, 2026FDA
Biosense Webster, Inc.PMA supplementSep 15, 2026FDA

Explore the linked device profile

Other records with product code OAE

Product / regulatory recordCompanyPathwayDecision dateSource
STOP Persistent AFP100010/S154
Medtronic Cryocath, LPPMA supplementSep 25, 2026FDA
ABBOTT MEDICALPMA supplementSep 22, 2026FDA
ABBOTT MEDICALPMA supplementSep 4, 2026FDA
St Jude MedicalPMA supplementAug 7, 2026FDA
ABBOTT MEDICALPMA supplementAug 7, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Biosense Webster, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
31 Technology Dr., Suite 200, Irvine, CA, 92618

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records